Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990 May 15;75(10):1928-31
Date
05/15/1990Pubmed ID
1692487Scopus ID
2-s2.0-0025337074 (requires institutional sign-in at Scopus site) 90 CitationsAbstract
Fludarabine, a fluorinated analogue of adenine, was given to 11 patients with macroglobulinemic lymphoma, all but one having failed prior standard chemotherapy. Five patients (45%) responded with more than a 50% reduction of immunoglobulin M (IgM) tumor mass for a projected median duration of longer than 1 year. The onset of remission was usually slow, with a median tumor halving time of 5.2 months in responding patients, emphasizing the importance of repeated courses of treatment. Fludarabine is an important new agent effective against macroglobulinemic lymphoma, and should be evaluated further in combination with other active modalities.
Author List
Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Antimetabolites, Antineoplastic
Arabinonucleotides
Female
Humans
Infusions, Intravenous
Lymphoma
Macroglobulins
Male
Middle Aged
Vidarabine Phosphate
Waldenstrom Macroglobulinemia
